DRugwatch BlogRSS 2.0

DRugwatch Blog > January 2012

  • 1/20/2012 2:12:09 PM
    A New Era and Market Opportunity for Multaq
    Matt Kileen 1/19/2012 6:15:13 PM
    Paula Deen and Questioning Celebrity Drug Endorsements
    Contributor: Allison Thrower

    If time and tradition are any indicators, celebrity pharmaceutical endorsements will be an advertising trend for years to come...
  • 1/17/2012 4:47:06 PM
    The current shortage of Doxil across the major markets
    Matt Kileen 1/9/2012 8:04:20 PM
    Diabetes Drug Development: 2011 Year in Review and a Look Ahead Towards 2012 And Beyond – Part 2
    Matt Kileen 1/6/2012 5:25:06 PM
    Diabetes Drug Development: 2011 Year in Review and a Look Ahead Towards 2012 And Beyond – Part 1
    Matt Kileen


    rss twitter linkedin


    DRugwatch Blog

    Quick insight on intriguing drug market developments from Decision Resources’ analysts.

    Recent posts

    Post title:
    New Year, new resolutions, new drugs
    Post date:
    12/17/2014 10:53:24 AM
    Post Summary:
     Contributors: Tim Blackstock

    It’s a wonderful time of the year: spending quality time with friends and family, and eating good food. And then it’s January, and you hop on the scales – and then you hop off quickly in disbelief – how can it take such a short time to add so many pounds when it takes so long to lose just a few?!

    Post title:
    Pfizer Increases Enrollment by 40% in the SPIRE Cardiovascular Outcomes Trials for PCSK9 Inhibitor Bococizumab
    Post date:
    11/11/2014 9:36:25 AM
    Post Summary:
    Gideon HeapGideon HeapContributors: Tim Blackstock and Conor Walsh

    The latest news from the battle of the PCSK9 inhibitors is that Pfizer has increased enrollment by approximately 40% in its SPIRE-1 and SPIRE-2 cardiovascular outcomes trials (CVOTs).

    Post title:
    Obesity Week 2014 - Belviq gets the combination treatment
    Post date:
    11/7/2014 10:07:43 AM
    Post Summary:
    Gideon HeapContributor: Gideon Heap

    Eisai has released results of a trial in which good old phentermine was added to the company’s obesity treatment, Belviq (lorcaserin). The primary endpoint for the trial was to discover if the combination increased the risk of patients having serotonergic adverse events (bad) after 12 weeks. It didn’t (good). However, twice as many patients (10.1%) on the combo dropped out due adverse events compared with Belviq alone.

    Post title:
    What’s going to be Hot at the 2014 AHA Scientific Sessions?
    Post date:
    10/22/2014 5:22:24 PM
    Post Summary:
      Contributor: Conor Walsh

     This year’s line-up of Late-Breaking Clinical Trial sessions looks very interesting; with many trials having the   potential to significantly impact clinical practice. The trial results will be presented over four days in separate sessions focusing on:

    • Risk and benefit of dual antiplatelet therapy (DAPT),
    • Anti-lipid therapy and prevention of coronary artery disease,
    • Treatment of structural heart disease
    • Drugs, devices and systems of care for ischemic heart disease.

    Post title:
    Advancing the Treatment of TKI-refractory NSCLC
    Post date:
    10/9/2014 1:33:46 PM
    Post Summary:
    Contributor: Orestis Mavroudis-Chocholis

    NSCLC is considered by many to be the poster child for personalized medicine in oncology. The approval of TKIs for the treatment of EGFR-mutation-positive and ALK-translocation-positive NSCLC patients has redefined the NSCLC treatment algorithm and developers are now in fierce competition to be the first to market novel, more efficacious and better tolerated TKIs which can be used as follow-on treatment options or replacements for currently approved front-line TKIs.

    Decision Resources Group brands include: